DISRUPT PAD III Observational Study

CompletedOBSERVATIONAL
Enrollment

1,373

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

June 10, 2021

Study Completion Date

June 10, 2021

Conditions
Peripheral Arterial Disease
Trial Locations (30)

10019

Mount Sinai West, New York

10032

Columbia University Medical Center, New York

17101

Pinnacle Health Cardiovascular Institute, Harrisburg

19010

Bryn Mawr Hospital, Bryn Mawr

20010

Medstar Washington Hospital Center, Washington D.C.

25304

Charleston Area Medical Center, Charleston

27607

NC Heart & Vascular Research, LLC, Raleigh

30309

Piedmont Heart Institute, Atlanta

30501

Northeast Georgia Medical Center, Gainesville

32308

Tallahassee Research Institute Inc., Tallahassee

38120

Baptist Medical Center, Memphis

38801

North Mississippi Medical Center, Tupelo

43214

Ohio Health Research Institute, Columbus

48341

St. Joseph Mercy Oakland, Pontiac

52803

Midwest Cardiovascular Research Foundation, Davenport

60007

Alexian Brothers Medical Center, Elk Grove Village

64111

St. Luke's Cardiovascular Consultants, Kansas City

74006

St. John Clinic, Bartlesville

77030

Baylor Clinic McNair Campus, Houston

78756

St. David's Heart and Vascular (Austin Heart), Austin

80045

Rocky Mountain Regional VA Medical Center, Aurora

80538

UCHealth Northern Colorado, Loveland

94304

Stanford Hospital, Palo Alto

97225

Providence Heart & Vascular Institute, Portland

02135

Steward St. Elizabeth's Medical Center, Brighton

02906

The Miriam Hospital, Providence

Unknown

Evangelisches Krankenhaus Mulheim an der Ruhr, Mülheim

St. Franziskus Hospital, Münster

RoMed Klinikum Rosenheim, Rosenheim

Auckland City Hospital, Auckland

All Listed Sponsors
lead

Shockwave Medical, Inc.

INDUSTRY

NCT05881421 - DISRUPT PAD III Observational Study | Biotech Hunter | Biotech Hunter